Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
July 16, 2024 09:02 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Disulfiram Presents a $521+ Million Industry Opportunity by 2030: Increasing Patient Awareness and Higher Treatment-Seeking Rate
June 21, 2024 09:22 ET
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Global Disulfiram Market by Indication (Alcoholism Treatment, Co-occurring Disorders), Distribution Channel (Hospital Pharmacies, Online Pharmacies,...
Alcohol Addiction Dug Pipeline Research Report 2024
April 11, 2024 09:33 ET
|
Research and Markets
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Alcohol Addiction - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report outlays comprehensive...
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
March 13, 2024 08:14 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery...
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
February 23, 2024 07:06 ET
|
Clearmind Medicine Inc.
For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
November 09, 2023 09:20 ET
|
Clearmind Medicine Inc.
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada,...
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
September 06, 2023 09:20 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
May 02, 2023 08:30 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, May 02, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Global Psychiatric and Substance Abuse Hospitals Market Report 2022: A $36.1 Billion Market by 2027 Featuring HCA Healthcare, NSW Health, Queensland Health, Tenet Healthcare, Universal Health Services
February 16, 2023 09:08 ET
|
Research and Markets
Dublin, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The "Psychiatric and Substance Abuse Hospitals: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global...
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
December 28, 2022 09:00 ET
|
Clearmind Medicine Inc.
Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well Tel Aviv, Israel / Vancouver, Canada, Dec. 28, 2022 (GLOBE...